Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price rose 15.4% on Wednesday . The company traded as high as C$0.24 and last traded at C$0.23. Approximately 382,000 shares traded hands during trading, a decline of 37% from the average daily volume of 601,939 shares. The stock had previously closed at C$0.20.
Hemostemix Stock Performance
The business has a fifty day moving average of C$0.10 and a 200-day moving average of C$0.08. The company has a market capitalization of C$19.60 million, a P/E ratio of -11.25 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Further Reading
- Five stocks we like better than Hemostemix
- Investing in Construction Stocks
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- What Goldman Sachs’ Quarterly Results Reveal About the Economy
- What is the Nasdaq? Complete Overview with History
- 3 Dividend Stocks at Bargain Levels to Defend Your Portfolio
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
